Spero Therapeutics (SPRO) Preferred Dividend Payments (2016 - 2017)
Spero Therapeutics' (SPRO) quarterly Preferred Dividend Payments came in at $833000.0 in Q4 2017, down 9.26% on a YoY basis from $918000.0 in Q4 2016, and down 59.41% quarter-over-quarter from $2.1 million in Q3 2017.
Powered by 
Analysis
Spero Therapeutics (SPRO) Preferred Dividend Payments (2016 - 2017) Analysis & Trends
Spero Therapeutics (SPRO) has reported Preferred Dividend Payments for 2 consecutive years, with $833000.0 the latest figure, recorded in Q4 2017.
- For the quarter ending Q4 2017, Preferred Dividend Payments fell 9.26% year-over-year to $833000.0; the trailing twelve-month figure through Dec 2017 stood at $6.1 million (changed N/A YoY), and the FY2017 full-year result was $6.1 million, up 78.61% from the prior year.
- Preferred Dividend Payments fell to $833000.0 in Q4 2017 per SPRO's latest filing, from $2.1 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $2.1 million in Q3 2017 and bottomed at $833000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Spero Therapeutics | 67.82 Mn | 17.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 833,000.00 |
| Sep 30, 2017 | 2.05 Mn |
| Jun 30, 2017 | 2.03 Mn |
| Mar 31, 2017 | 1.24 Mn |
| Dec 31, 2016 | 918,000.00 |
| Sep 30, 2016 | 916,000.00 |